Pressure BioSciences (OTCQB: PBIO) has announced its CEO will be participating in the upcoming Emerging Growth Conference. PBIO is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences, agriculture, food & beverage, and other key industries. Slated for June 23, the real-time, interactive investor conference has scheduled 10 companies to present for 30-45 minutes each; PBIO will be one of those companies. PBIO president and CEO Richard T. Schumacher will represent the company. His presentation, which is scheduled to start at 1:30 p.m. ET, will feature a corporate overview as well as a summary of company highlights, including the company’s resurgent growth (PBIO just reported its strongest financial quarter in three years), its plans to acquire the assets of a global eco-friendly agrochemical supplier and the formation of a food industry consortium with the primary objective of advancing commercialization of the company’s UST (“UST”) platform for producing the highest-quality food and beverage nanoemulsions with long-term room-temperature storage stability and optimized flavor and nutrition profiles. Schumacher will also talk about the company’s collaboration with SinuSys Corporation and the breakthrough potential of its partnership with LEICA Microsystems to develop more efficient cancer diagnostics as well as PBIO’s four recently filed patents covering the UST platform.
To register for the event, visit https://ibn.fm/iYDKn
To view the full press release, visit https://ibn.fm/Byppx
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector, and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
